...with moderate to severe atopic dermatitis. NIH stops hydroxychloroquine trial On Saturday, NIH stopped its ORCHID...

...its EUA decision. FDA may be waiting for results from the 510-patient randomized, controlled NIH-funded ORCHID...
...April. Study completion is scheduled for July, but some results could be announced sooner. If ORCHID...

...combination with the antibiotic azithromycin. NIH and Massachusetts General Hospital are running the Phase III ORCHID...

...than 500 adults hospitalized with COVID-19, or in an emergency department with anticipated hospitalization. The ORCHID...

...Not applicable Hospital-acquired bacterial infections Fedora Pharmaceuticals Inc. FPI-1465 Not applicable Not applicable Bacterial infections Orchid...

...be effective in previous studies. Roche filed suit against Actavis, Apotex, Dr. Reddy's, Mylan and Orchid...
...Toronto, Ontario Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Orchid...

...Archemix Corp.; Arca biopharma Inc. (NASDAQ:ABIO) ARC2172 (aptamer) Phase I Block coagulation Diakron Pharmaceutical Inc.; Orchid...

...to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid...
...April co-led by Edmond de Rothschild Investment Partners and Forbion Capital Partners, with participation by Orchid...
...is one of the compounds acquired from Orchid. "The patents that we have acquired from Orchid...

...treat and prevent postmenopausal osteoporosis. Apotex Inc. (Toronto, Ontario); Mylan Inc. (NASDAQ:MYL, Canonsburg, Pa.); and Orchid...

...Materials development company Nanologica joined the ORCHID alliance to improve the formulation and solubility of water-insoluble...
...porous carrier materials to control the release of active compounds through porous particles. The four-year ORCHID...
...EU is directly contributing €5.4 million ($7.2 million) in funding to the project. Members of ORCHID...